A significant London Drugs leadership transition is underway as longtime president and chief operating officer Clint Mahlman prepares to retire on May 29, 2026, following a 41-year career with one of Western Canada’s most established retailers.

Mahlman’s departure marks the end of an era for the Richmond, British Columbia-based company, which operates 78 stores across more than 35 markets in British Columbia, Alberta, Saskatchewan, and Manitoba. The business is owned by H.Y. Louie Co. Limited and remains one of the country’s most distinctive retail formats, combining pharmacy, electronics, cosmetics, and general merchandise under one roof.

From Stockroom to President: A Four-Decade Career

Mahlman’s career trajectory reflects a rare, fully internal rise through the organization. He joined London Drugs in 1984 as a part-time stock boy at its Kingsway location in Vancouver while studying at the British Columbia Institute of Technology.

Within a year, he moved into a sales supervisor role and became a store manager by 1990. Over the following decades, he progressed through regional and corporate leadership positions, including Director of Human Resources in 1997 and Vice-President of Human Resources and Distribution in 1998. He joined the executive committee in 2000, became Senior Vice-President in 2007, and was appointed Chief Operating Officer in 2012.

In 2014, following the retirement of former president Wynne Powell, Mahlman assumed the role of Executive Vice-President while continuing as COO. He was formally named President in 2018 by CEO Brandt Louie, solidifying his position as the company’s top operational leader.

His path to leadership was unconventional. Growing up in Gibsons, British Columbia, Mahlman worked in fishing, logging, and pulp mill operations before entering retail. He originally aspired to become a national park warden, but pursued business studies in Vancouver when federal hiring slowed in the 1980s.

Leadership Approach and Strategic Initiatives

Mahlman’s leadership has often been defined by a long-term approach to customer relationships and employee engagement. He has described his philosophy as “servant leadership,” with a focus on the lifetime value of customers rather than short-term transactions.

During his tenure, London Drugs expanded its reputation as a differentiated retailer. The company invested heavily in e-commerce, positioning its online platform as a “virtual store” to compete with larger global players. At the same time, it continued to emphasize high-touch in-store services, including pharmacy consultations and technology support.

Mahlman also led sustainability efforts through initiatives such as the “What’s the Green Deal?” program, which established London Drugs as an early leader in retail recycling and environmental stewardship. More recently, he oversaw the rollout of new “DaVinci” store formats designed to create more intuitive, human-centered retail environments, including a prominent location at CF Polo Park in Winnipeg.

Navigating Crisis and Industry Challenges

The final chapter of Mahlman’s leadership included significant operational and industry challenges. In 2024, London Drugs experienced a major cybersecurity incident that forced the temporary closure of all stores for over a week. Mahlman led the company’s response and recovery efforts during that period.

He also became an outspoken advocate for retail safety, particularly in British Columbia. As organized retail crime and in-store incidents increased, Mahlman participated in advocacy efforts calling for stronger government action. His involvement included highlighting the need for enhanced protections for frontline retail staff.

These efforts reflected a broader shift in industry discussions, moving beyond financial losses toward concerns about employee safety and store environments.

Nick Curalli Named Successor

As part of this London Drugs leadership transition, the company has appointed Nick Curalli as President and Chief Operating Officer, effective May 29, 2026.

Curalli brings more than 30 years of experience with London Drugs, having started his career as General Manager for Information Technology. Most recently, he served as Vice-President of Technology Solutions and has also held the role of Chief Privacy Officer.

His appointment signals a continued focus on technology and cybersecurity within the organization. Curalli has been involved in several innovation initiatives, including in-store digital tools to support product comparison and operational technology projects aimed at improving efficiency and customer experience.

The decision to name a successor immediately also represents a shift from past practice. Following Wynne Powell’s retirement in 2014, the company operated without a formal president until Mahlman was elevated to the role in 2018.

A Culture of Internal Promotion

The leadership change underscores a longstanding cultural characteristic within London Drugs and its parent organization, H.Y. Louie Co. Limited. Both Mahlman and Curalli built their careers entirely within the company, representing a combined tenure of more than 70 years.

This approach aligns with the broader leadership philosophy of the Louie family, whose retail roots date back to 1903 when Hok Yat Louie founded a general store in Vancouver’s Chinatown. The family later expanded the business significantly, including the acquisition of London Drugs in 1976 under Tong Louie.

The group’s holdings also include grocery operations through Georgia Main Food Group, which manages banners such as IGA Marketplace and Fresh St. Market in British Columbia.

More from Retail Insider:

• Clint Mahlman Leading Legendary Retailer London Drugs Toward Further Success, Growth and Differentiation [Feature]
• London Drugs’ Clint Mahlman Wins Prestigious Canadian Retailer of the Year Award
• London Drugs to Close Downtown Eastside Vancouver Store
• London Drugs Expands with New Winnipeg Location
• As Retailers Collect More Data, Cybercrime Hits Retailers Including London Drugs [Expert Comments]